Telomir Pharmaceuticals (NASDAQ:TELO) Releases Earnings Results, Misses Estimates By $0.05 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) released its quarterly earnings data on Tuesday. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05), Zacks reports.

Telomir Pharmaceuticals Stock Performance

TELO traded up $0.34 during midday trading on Tuesday, reaching $4.51. 128,303 shares of the company were exchanged, compared to its average volume of 114,327. Telomir Pharmaceuticals has a one year low of $3.11 and a one year high of $20.72. The company’s fifty day moving average price is $4.74 and its 200 day moving average price is $4.81.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.